Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors

Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors
imageStock Markets23 minutes ago (Aug 06, 2020 07:05AM ET)

(C) Reuters. Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

(Reuters) – Bristol Myers Squibb Co (N:BMY) raised its annual profit forecast on Thursday on hopes of a recovery in demand for its hospital-administered drugs, which had dropped as patients stayed away from doctors’ offices due to the COVID-19 pandemic.

The U.S. drugmaker said it expects demand from new patients and for its products administered by doctors to start recovering in the third quarter and fully recovery in the fourth quarter.

Other companies such as Pfizer Inc (N:PFE) and Bristol’s close rival Merck & Co (N:MRK) also expect medical visits to return to normal by the fourth quarter.

Bristol now expects full-year adjusted profit of $6.10 to $6.25 per share, up from its prior range of $6-$6.20 per share.

The company’s total revenue rose 61.5% to $10.13 billion in the second quarter, above Refinitiv estimate of $9.97 billion, mainly due to its $74 billion buyout of Celgene (NASDAQ:CELG).

Sales of its cancer drug Opdivo, however, fell 9% to $1.65 billion, roughly in line with analysts’ estimates. Sales of blood thinner Eliquis, which it shares with Pfizer, rose 6% to $2.16 billion.

Bristol reported a net loss of $85 million, or 4 cents per share, in the quarter ended June 30, compared with a profit of $1.43 billion, or 87 cents per share, mainly due to amortization of assets and higher costs from the Celgene deal.

Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave a Reply

Your email address will not be published. Required fields are marked *